Final Results

Surgical Innovations Group PLC 29 April 2004 Surgical Innovations Group plc Preliminary results for the year ended 31 December 2003 29 April 2004 CHAIRMAN'S STATEMENT Once again, I am delighted to report further progress in your Group's overall performance in the year 2003. Group turnover increased from £2.22 million in 2002 to £2.75 million in 2003, an increase of 24%, which has resulted in a pre-tax profit of £136k compared with £60k in the previous year. Furthermore, our order book is currently at a record level. As detailed in the recent April press release, I am pleased to confirm that we have signed a cross-licensing agreement with Applied Medical Resources. Under the terms of the agreement, the Group will retain the manufacturing, marketing and distribution rights to Variglide for up to three years. Thereafter, Applied Medical Resources will be granted worldwide manufacturing and distribution rights in return for royalty payments. In addition, the Group will be provided with an indefinite licence for YelloPort, our reusable port access system, and unlimited access into the US market. Importantly, the agreement removes any potential concerns regarding the patent position of both systems. Furthermore, following constructive discussions, we have agreed to co-operate more closely to explore future opportunities that may lead to mutually beneficial product development projects. I see this as an important step in our ongoing commitment to increasing shareholder value. Our royalty income from the global sales of Endoflex by Snowden Pencer has been strengthened by the sales of Goldfinger, an Endoflex derivative, to Ethicon. As part of its move into the growing area of anti-obesity surgery, Ethicon uses Goldfinger as a key device in the deployment of its gastric band. The overall contribution from royalties for 2003 was £394k. In line with our product development programme, these royalties were reinvested in research and development expenditure of £318k. This represents 12% of turnover, which emphasises our commitment to this vital area. 2003 resulted in a further increase in sales of our single-use scissors and our reusable YelloPort system as the relationships between the Group and our strategic partners continued to flourish. I am proud that we are associated with internationally renowned medical device companies such as Aesculap, Cardinal Health, Applied Medical Resources and Pilling Weck. These partnerships are resulting in new product ideas and increased opportunities to promote our quality laparoscopic devices. As Chairman of Surgical Innovations, I appreciate that the majority of our success has been generated from products for minimally invasive surgery. However, we remain fully aware of the potential for the Group in the field of Autologous Blood Transfusion (ABT) and we have been waiting until we are able to generate sufficient profits from the other sectors before committing to the levels of expenditure needed to enhance our current ABT product range. 2004 will be an important year in this regard as we begin to manufacture our post- operative products in a new manufacturing facility. In the UK, the post- operative ABT products are gaining popularity and with the current issues surrounding donated blood, I anticipate sustained interest and growth for ABT. 2003 proved to be successful in establishing a platform on which we can now push ahead in all areas of our business. With the current order book at the highest ever level and the necessary resources now in place to satisfy demand, we approach 2004 with optimism for further growth in sales and profitability. Once again, on your behalf, I wish to thank my Board colleagues and all the Group's employees for their continued dedication and commitment and I look forward to reporting further progress during the current year. Doug Liversidge CBE Chairman 28 April 2004 Consolidated Profit and Loss Account For the year ended 31 December 2003 Notes 2003 2002 £'000 £'000 Turnover (including Royalties) 2,750 2,224 Cost of sales (1,312) (1,048) Gross profit 1,438 1,176 Administrative expenses (1,255) (1,098) Operating profit 183 78 Interest receivable - 1 Interest payable (47) (19) Profit on ordinary activities for the year before taxation 136 60 Tax on profit on ordinary activities 3 18 Retained profit for the year 139 78 Earnings per ordinary share 2 0.05p 0.03p Consolidated Balance Sheet As at 31 December 2003 2003 2002 £'000 £'000 £'000 £'000 Fixed assets Tangible assets 892 660 Current assets Stocks 721 562 Debtors 1,245 1,073 Cash at bank - 13 1,966 1,648 Creditors: amounts falling due within one year (1,111) (775) Net current assets 855 873 Total assets less current liabilities 1,747 1,533 Creditors: amounts falling due after more than one year (352) (285) Net assets 1,395 1,248 Capital and reserves Called up share capital 2,559 2,555 Share premium account 16,048 16,044 Capital reserve 329 329 Accumulated losses (17,541) (17,680) (1,164) (1,307) Equity shareholders' funds 1,395 1,248 Consolidated Cash Flow Statement For the year ended 31 December 2003 Notes 2003 2002 £'000 £'000 £'000 £'000 Net cash inflow /(outflow) from operating activities 3 265 (141) Returns on investments and servicing of finance Interest payable on finance leases (23) (10) Interest payable on bank overdrafts (17) (2) Interest payable on convertible loan notes (7) (7) Interest receivable - 1 Net cash outflow from returns on investments and servicing of finance (47) (18) Taxation 37 11 Capital Expenditure: purchases of tangible fixed assets (158) (207) Net Cash inflow/(outflow) before financing 97 (355) Financing Issue of shares - 3 Receipts from borrowings - 9 Capital repayments under bank loans (3) (1) Capital repayment under finances (63) (22) Net cash outflow from financing (66) (11) Increase/(decrease) in cash 4 31 (366) Notes For the year ended 31 December 2003 1. Accounting policies The principal accounting policies which remain unchanged from the previous year, are as follows: a) Basis of accounting The financial statements have been prepared under the historical cost basis of accounting and in accordance with applicable Accounting Standards in the United Kingdom. b) Basis of consolidation The Group financial statement consolidate those of the Company and of its subsidiary undertakings drawn up to 31 December 2003. The results of subsidiaries accounted for under the acquisition accounting method are included in the consolidated profit and loss from the date of their acquisition. The results of subsidiaries, accounted for under the merger accounting method, are included in the consolidated profit and loss account as if they had always been part of the Group. Intra-Group sales and results are eliminated on consolidation and all sales and results relate to external transactions only. 2. Earnings per ordinary share The earnings per ordinary share has been calculated by dividing the profit attributable to ordinary shareholders for the year ended 31 December 2003 of £139,000 (2002 : £78,000) by the weighted average number of ordinary shares in issue during the year of 255,659,894 (2002 : 254,995,289) and amounted to 0.05p per share (2002 : 0.03p per share). 3. Net cash inflow/(outflow) from operating activities 2003 2002 £'000 £'000 Operating profit 183 78 Depreciation of tangible fixed assets 104 88 Increase in stocks (159) (13) Increase in debtors (206) (241) Increase / (decrease) in creditors 343 (53) 265 (141) 4. Reconciliation of net cash flow to movement in net debt 2003 2002 £'000 £'000 Increase/(decrease) in cash in the year 31 (366) Cash outflow from finance leases and loans 66 14 Change in net debt resulting from cash flows 97 (352) Conversion of loan notes - 1 New finance leases (178) (259) Movement in net debt (81) (610) Net debt at beginning of year (559) 51 Net debt at end of year (640) (559) 5. Analysis of changes in net debt At Cash Non-cash At 1 January flow changes 31 December 2003 2003 £'000 £'000 £'000 £'000 Cash at bank and in hand 13 (13) - - Bank overdrafts (217) 44 - (173) 31 Bank loan (8) 3 - (5) Finance leases (237) 63 (178) (352) 66 Convertible loan notes (110) - - (110) (559) 97 (178) (640) 6. The Annual General Meeting of the Company will be held at the Village Hotel and Leisure Club, 186 Otley Road, Headingley Leeds LS16 5PR at 11.30am on Wednesday, 2 June 2003. 7. The foregoing statements do not constitute the Group's statutory accounts. The Group's statutory accounts, on which the Company's auditors, Grant Thornton, have given an unqualified opinion in accordance with Section 235 of the Companies Act 1985, are to be delivered to the Registrar of Companies and will be posted to shareholders shortly. Additional copies of the Annual Report and of this announcement will be available at the Company's registered office: Clayton Park, Clayton Wood Rise, Leeds, LS16 6RF Enquiries: Surgical Innovations Group plc Graham Bowland, Finance Director Tel: +44 (0) 113 230 7597 Westhouse Securities LLP Philip Johnson Tel: +44 (0) 161 838 9140 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings